Menu
Search
|

Menu

Close
X

Celcuity Inc CELC.OQ (NASDAQ Stock Exchange Capital Market)

22.30 USD
-- (--)
As of Jul 18
chart
Previous Close 22.30
Open --
Volume --
3m Avg Volume 9,794
Today’s High --
Today’s Low --
52 Week High 29.19
52 Week Low 11.10
Shares Outstanding (mil) 10.11
Market Capitalization (mil) 229.43
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.195
FY17
-0.759
FY16
-0.395
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.89
Price to Sales (TTM)
vs sector
--
8.00
Price to Book (MRQ)
vs sector
7.53
4.21
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
0.00
17.41
LT Debt to Equity (MRQ)
vs sector
0.00
13.26
Return on Investment (TTM)
vs sector
-43.84
13.14
Return on Equity (TTM)
vs sector
-43.84
15.15

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

16305 36th Ave N Ste 450
MINNEAPOLIS   MN   55446-4280

Phone: +1763.3920767

Celcuity, Inc. is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it. CELx platform provides traditional molecular diagnostics, which provides a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival.

SPONSORED STORIES